Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE MKT: SNT),
announced today that the characteristics and activity of SNS01 have been
released on-line in Molecular Therapy, the official journal of the
American Society for Gene & Cell Therapy. The print version of the
article is scheduled to be published during the summer. http://www.nature.com/mt/journal/vaop/ncurrent/full/mt201294a.html
"SNS01 is an earlier formulation of Senesco's therapeutic candidate
SNS01-T, which is currently being evaluated in a Phase 1b/2a clinical
study to treat patients with relapsed or refractory multiple myeloma,"
said Leslie J. Browne, Ph.D., President and CEO of Senesco. "SNS01
helped us to establish the benefits of modulating the eIF5A pathway to
selectively trigger programmed cell death in malignant B-cells and to
develop a more potent and better tolerated version to take into clinical
trials."
The Company recently announced the oral presentation, entitled "SNS01-T,
an eIF5A-Based Gene Therapy Nanoparticle Designed for the Treatment of
Multiple Myeloma, has Anti-Tumoral Activity in Lymphoma", which
described the effectiveness of SNS01-T in B-cell cancers. Research for
both publications was performed in Senesco CSO John Thompson's research
laboratory at the University of Waterloo in Ontario, Canada.
Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy